177 related articles for article (PubMed ID: 30946371)
1. Efficacy of carboplatin plus S-1 for the treatment of non-small cell lung cancer: A protocol for a systematic review of randomized controlled trial.
Han L; Wei ZX; Lv YF; Jiang AY
Medicine (Baltimore); 2019 Apr; 98(14):e15099. PubMed ID: 30946371
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of S-1 in combination with carboplatin in non-small cell lung cancer patients with interstitial lung disease: a pilot study.
Sekine A; Satoh H; Baba T; Ikeda S; Okuda R; Shinohara T; Komatsu S; Hagiwara E; Iwasawa T; Ogura T; Kato T
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1245-52. PubMed ID: 27130459
[TBL] [Abstract][Full Text] [Related]
3. Comparative efficacy of Chinese herbal injections combined with GP regimen chemotherapy for patients with advanced NSCLC: A protocol for systematic review and network meta-analysis.
Li J; Zhu GH; Liu TT; Xu BW; Li J
Medicine (Baltimore); 2020 Jul; 99(28):e21041. PubMed ID: 32664114
[TBL] [Abstract][Full Text] [Related]
4. S-1-based concurrent chemoradiotherapy in the treatment of locally advanced non-small cell lung cancer: A systematic review and meta-analysis protocol.
Liu F; Wang C; Hu T; Wang W
Medicine (Baltimore); 2018 Apr; 97(15):e0397. PubMed ID: 29642202
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of Shenqi Fuzheng injection combined with platinum-based chemotherapy for stage III/IV non-small cell lung cancer: A protocol for systematic review and meta-analysis of randomized controlled trials.
Chen H; Yao X; Liu Z; Li T; Xu C; Wang J; Sui X; Leung EL; Wu Q
Medicine (Baltimore); 2019 Sep; 98(39):e17350. PubMed ID: 31574877
[TBL] [Abstract][Full Text] [Related]
6. A Phase II Study of Tailored-dose S-1 Plus Carboplatin Followed by Maintenance S-1 for Advanced Squamous Cell Lung Cancer: OSAKA-LCSG 1102.
Yokoi T; Minami S; Shiroyama T; Koba T; Torii Y; Sugimoto H; Niki M; Mori M; Morimura O; Hirashima T; Komuta K; Kijima T
Intern Med; 2019 May; 58(10):1405-1410. PubMed ID: 30713297
[TBL] [Abstract][Full Text] [Related]
7. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety analysis according to histology for S-1 in combination with carboplatin as first-line chemotherapy in patients with advanced non-small-cell lung cancer: updated results of the West Japan Oncology Group LETS study.
Yoshioka H; Okamoto I; Morita S; Ando M; Takeda K; Seto T; Yamamoto N; Saka H; Atagi S; Hirashima T; Kudoh S; Satouchi M; Ikeda N; Iwamoto Y; Sawa T; Nakanishi Y; Nakagawa K
Ann Oncol; 2013 May; 24(5):1326-31. PubMed ID: 23277482
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer.
Vasconcellos VF; Marta GN; da Silva EM; Gois AF; de Castria TB; Riera R
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD009256. PubMed ID: 31930743
[TBL] [Abstract][Full Text] [Related]
10. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
11. Carboplatin, S-1 and concurrent thoracic radiotherapy for elderly patients with locally advanced non-small cell lung cancer: a multicenter Phase I/II study.
Niho S; Hosomi Y; Okamoto H; Nihei K; Tanaka H; Hida T; Umemura S; Goto K; Akimoto T; Ohe Y
Jpn J Clin Oncol; 2019 Jul; 49(7):614-619. PubMed ID: 30916304
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of cinobufacini injection combined with vinorelbine and cisplatin regimen chemotherapy for stage III/IV non-small cell lung cancer: A protocol for systematic review and meta-analysis of randomized controlled trials.
Li Q; Liang RL; Yu QR; Tian DQ; Zhao LN; Wang WW; Xiao H; Yong XJ; Peng XD
Medicine (Baltimore); 2020 Jul; 99(31):e21539. PubMed ID: 32756206
[TBL] [Abstract][Full Text] [Related]
13. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
14. Postoperative adjuvant therapy for resectable early non-small cell lung cancer: A protocol for a systematic review and meta-analysis.
Chai T; Zhang P; Lin Y; Zhang Z; Lin W; Kang M; Lin J
Medicine (Baltimore); 2019 Jul; 98(30):e16468. PubMed ID: 31348250
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of S-1 in non-small cell lung cancer.
Kawahara M
Expert Opin Pharmacother; 2014 Sep; 15(13):1927-42. PubMed ID: 25109221
[TBL] [Abstract][Full Text] [Related]
16. Compound Kushen injection plus platinum-based chemotherapy for stage IIIB/IV non-small cell lung cancer: A protocol for meta-analysis of randomized clinical trials following the PRISMA guidelines.
Chen H; Yao X; Li T; Lam CW; Zhang H; Wang J; Zhang W; Leung EL; Wu Q
Medicine (Baltimore); 2019 Dec; 98(52):e18552. PubMed ID: 31876753
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of S-1 plus cisplatin combined with bevacizumab for advanced non-squamous non-small cell lung cancer (TCOG LC-1202).
Miyanaga A; Kubota K; Hosomi Y; Okuma Y; Minato K; Fujimoto S; Okamoto H; Satouchi M; Isobe H; Aono H; Takiguchi Y; Gemma A;
Jpn J Clin Oncol; 2019 Aug; 49(8):749-754. PubMed ID: 31070750
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the efficacy and safety of single-agent erlotinib and doublet molecular targeted agents based on erlotinib in advanced non-small cell lung cancer (NSCLC): a systematic review and meta-analysis.
Pan G; Ke S; Zhao J
Target Oncol; 2013 Jun; 8(2):107-16. PubMed ID: 23516098
[TBL] [Abstract][Full Text] [Related]
19. Anlotinib Combined with S-1 in the Third-Line Treatment of Stage IV Non-Small Cell Lung Cancer: Study Protocol for Phase II Clinical Trial.
Yang X; Xiang M; Geng L; Wen Y; Du X
Asian Pac J Cancer Prev; 2019 Dec; 20(12):3849-3853. PubMed ID: 31870132
[TBL] [Abstract][Full Text] [Related]
20. A multicenter, open-label, phase II trial of S-1 plus carboplatin in advanced non-small cell lung cancer patients with interstitial lung disease.
Hanibuchi M; Kakiuchi S; Atagi S; Ogushi F; Shimizu E; Haku T; Toyoda Y; Azuma M; Kondo M; Kawano H; Otsuka K; Sakaguchi S; Nokihara H; Goto H; Nishioka Y
Lung Cancer; 2018 Nov; 125():93-99. PubMed ID: 30429044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
